Tuvirumab
Tuvirumab is a human monoclonal antibody for the treatment of patients with chronic hepatitis B. It has undergone Phase I clinical trials in 2001.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | hepatitis B virus |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| (verify) | |
References
- Heijtink RA, van Nunen AB, van Bergen P, Ostberg L, Osterhaus AD, de Man RA (August 2001). "Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes". Journal of Medical Virology. 64 (4): 427–34. doi:10.1002/jmv.1068. PMID 11468726.
- van Nunen AB, Baumann M, Manns MP, Reichen J, Spengler U, Marschner JP, de Man RA (June 2001). "Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients". Liver. 21 (3): 207–12. doi:10.1034/j.1600-0676.2001.021003207.x. PMID 11422784.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.